GW501516
GW501516 (also known as GW-501,516, GW1516, GSK-516 and on the black market as Endurobol) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s, was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases, and was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.
GW501516
GW501516 (also known as GW-501,516, GW1516, GSK-516 and on the black market as Endurobol) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s, was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases, and was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.
has abstract
GW1516 (другие названия: GW151 ...... я, возникающих при его приёме.
@ru
GW501516 (also known as GW-501 ...... tes that GW501516 is not safe.
@en
La molécula GW501516 (conocida ...... su alto potencial cancerígeno.
@es
ATC prefix
CAS number
317318-70-0
ChEBI
IUPAC name
{4-[({4-methyl-2-[4-(trifluoro ...... l]-2-methylphenoxy}acetic acid
@en
PubChem
thumbnail
Wikipage page ID
16,366,361
Wikipage revision ID
738,753,551
ChEMBL
ChemSpiderID
IUPHAR ligand
legal AU
legal UK
legal US
molecular weight
4.53498e+2
pregnancy category
routes of administration
StdInChIKey
YDBLKRPLXZNVNB-UHFFFAOYSA-N
Verifiedfields
verifiedrevid
458,657,924
hypernym
comment
GW1516 (другие названия: GW151 ...... было обнаружено у нескольких и
@ru
GW501516 (also known as GW-501 ...... lop rapidly in several organs.
@en
La molécula GW501516 (conocida ...... e las sustancias por separado.
@es
label
GW501516
@en
GW501516
@es
GW501516
@ru
